NEW YORK, NY–(Newsfile Corporation – January 4, 2025) – Leading securities law firm Bleichmar Fonty & Auld LLP BioAge Labs, Inc. for potential violations of federal securities laws. (NASDAQ: BIOA) announces investigation into
If you have invested in BioAge, you are encouraged to visit here for additional information https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Why is BioAge being tested?
Bioage Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The company’s lead product candidate, azelprag, is an orally available small-molecule agonist of the apelin receptor (APJ), designed for weight loss.
During the corresponding period, the company said that azelaprag was well tolerated in 265 individuals in eight Phase 1 clinical trials and that it was “well equipped to advance our clinical programs” after the company’s IPO.[.]”
The stock drops as the truth is revealed
On December 6, 2024, BioAge announced that it had stopped its STRIDES Phase 2 trial for azelprag, citing safety concerns, after liver transaminases were observed in subjects receiving azelprag. The company said the decision to stop the Strides Phase 2 study of azelaprag “became evident” “due to the safety profile of the current doses tested”.[.]”
The news caused the company’s stock price to drop more than 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.
Click here for more information: https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
What can you do?
If you have invested in BioAge you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, at no cost to you. Shareholders are not liable for any court costs or litigation expenses. The firm will seek court approval for any potential fees and charges.
Submit your information by going to:
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Why Bleachmar Fonty & Old LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 Plaintiffs Law Firms in 2023 by ISS SCAS and its attorneys have been named Titans of the Plaintiffs Bar by Law360 and Superlawyers by Thomson Reuters. Among its recent notable successes, BFA has acquired Tesla (NASDAQ: ), Inc. of the Board of Directors (pending court approval), as well as Teva Pharmaceutical (NYSE: ) Ind. Ltd. recovered over $900 million in value from
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Attorney advertising. Past results do not guarantee future results.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235856
